- AB-001
- A-PIMO
- (Adamantoyl) JWH-018
- 1-Pentyl-3-(1-adamantoyl)indole
EMCDDA. New drugs in Europe, 2011, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Apr 2012. 401 kB.
Hess, C; Murach, J; Krueger, L; Scharrenbroch, L; Unger, M; Madea, B; Sydow, K. Simultaneous detection of 93 synthetic cannabinoids by liquid chromatography-tandem mass spectrometry and retrospective application to real forensic samples. Drug Test. Anal., 1 May 2017, 9 (5), 721-733. 267 kB. https://doi.org/10.1002/dta.2030 #AB-001 LC,MS
Uchiyama, N; Kawamura, M; Kikura-Hanajiri, R; Goda, Y. URB-754: A new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci. Int., 10 Apr 2013, 227 (1), 21-32. 1.8 MB. https://doi.org/10.1016/j.forsciint.2012.08.047 #XIV
Jankovics, P; Váradi, A; Tölgyesi, L; Lohner, S; Németh-Palotás, J; Balla, J. Detection and identification of the new potential synthetic cannabinoids 1-pentyl-3-(2-iodobenzoyl)indole and 1-pentyl-3-(1-adamantoyl)indole in seized bulk powders in Hungary. Forensic Sci. Int., 1 Jan 2012, 214 (1-3), 27-32. 703 kB. https://doi.org/10.1016/j.forsciint.2011.07.011 #4
Kneisel, S; Auwärter, V; Kempf, J. Analysis of 30 synthetic cannabinoids in oral fluid using liquid chromatography-electrospray ionization tandem mass spectrometry. Drug Test. Anal., 1 Aug 2013, 5 (8), 657-669. 285 kB. https://doi.org/10.1002/dta.1429
Kavanagh, PV; Power, JD. New psychoactive substances legislation in Ireland – Perspectives from academia. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 884-891. 1.2 MB. https://doi.org/10.1002/dta.1598
Grigoryev, A; Kavanagh, P; Melnik, A. The detection of the urinary metabolites of 3-[(adamantan-1-yl)carbonyl]-1-pentylindole (AB-001), a novel cannabimimetic, by gas chromatography-mass spectrometry. Drug Test. Anal., 1 Jun 2012, 4 (6), 519-524. 205 kB. https://doi.org/10.1002/dta.350
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: Origins. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 165-190. 906 kB. https://doi.org/10.1007/164_2018_143 #62
Abbate, V; Schwenk, M; Presley, BC; Uchiyama, N. The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report). Pure Appl. Chem., 28 Aug 2018, 90 (8), 1255–1282. 1.0 MB. https://doi.org/10.1515/pac-2017-0605 #5. AB-001
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonist new psychoactive substances: Evolution. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 191-226. 1.2 MB. https://doi.org/10.1007/164_2018_144 #6
Wilkinson, SM; Banister, SD; Kassiou, M. Bioisosteric fluorine in the clandestine design of synthetic cannabinoids. Aust. J. Chem., 10 Feb 2015, 68 (1), 4–8. 451 kB. https://doi.org/10.1071/CH14198 #26
Banister, SD; Wilkinson, SM; Longworth, M; Stuart, J; Apetz, N; English, K; Brooker, L; Goebel, C; Hibbs, DE; Glass, M; Connor, M; McGregor, IS; Kassiou, M. The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse. ACS Chem. Neurosci., 17 Jul 2013, 4 (7), 1081–1092. 2.7 MB. https://doi.org/10.1021/cn400035r #5 MS,NMR